9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Pembrolizumab in Treating Patients With Malignant Mesothelioma

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Biphasic Mesothelioma

Estimated Enrollment: 65

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Ability of PD-L1 to predict response,  Overall survival (OS),  Progression free survival (PFS), Disease control rate (CR + PR + SD)

Interventions: Pembrolizumab, Laboratory Biomarker Analysis

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: March 2020

Completion Date: March 2020

Last  Posted Date: March 5, 2018

Location: University of Chicago, Chicago, Illinois, United States

Website Link: https://ClinicalTrials.gov/show/NCT02399371

Was this article helpful?
Dislike 0